Navigation Links
Arena Pharmaceuticals Announces Merck Discontinues Development of Investigational Niacin Receptor Agonist Program for Atherosclerosis
Date:12/23/2009

mportant class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin for weight management, has completed a pivotal Phase 3 clinical trial program. Arena submitted lorcaserin's New Drug Application to the FDA in December 2009.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the development, therapeutic indication and use, tolerability, safety, and efficacy of MK-1903; the discontinuation of Arena's collaboration with Merck; future collaborative activities; the regulatory approval of lorcaserin; and Arena's focus, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, regulatory authorities may not accept Arena's NDA submission; regulatory authorities may not find data from Arena's clinical trials and studies sufficient for regulatory approval; the timing, success and cost of Arena's lorcaserin program and other of its research and development programs; the timing and ability of Arena to receive regulatory approval for its drug candidates; results of clinical trials or preclinical studies may not be predictive of future results; clinical trials and studies may not proceed at the time or in the manner Arena expects or at all; Arena's ability to partner or commercialize lorcaserin or other of its compounds or programs; Arena's ability to obtain additional funds; Arena's ability to obtain and defend its p
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Medizone International Takes Aim at the Bioterrorism Countermeasures Arena
2. Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
3. Arena Pharmaceuticals to Present at the UBS Global Life Sciences Conference
4. Arena Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference
5. Arena Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
6. Arena Pharmaceuticals Announces First Quarter 2009 Financial Results
7. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, May 11, 2009
8. Arena Pharmaceuticals Obtains Equity Financing Commitment of Up to $50 Million
9. Arena Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference
10. Arena Pharmaceuticals to Present at the Oppenheimer 19th Annual Healthcare Conference
11. Arena Pharmaceuticals to Report Third Quarter 2008 Financial Results and to Host Conference Call and Webcast on Thursday, October 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... York, NY - July 24, 2014 -- Keryx Biopharmaceuticals, ... from the long-term, randomized, active control Phase 3 study ... iron-based phosphate binder, for the treatment of hyperphosphatemia in ... PERFECTED study (PhosphatE binding and iRon delivery with FErric ... Journal of the American Society of Nephrology ...
(Date:7/24/2014)... 24, 2014 -- A novel combination of microscopy and ... Energy,s Oak Ridge National Laboratory an unprecedented look at ... physical and electrochemical properties. , The research team ... the surface of a perovskite manganite, a complex material ... avenue to understand surface behavior could benefit researchers who ...
(Date:7/24/2014)... 24, 2014 Gain recognition for ... Chain of the biotech industry. Nominations are now ... brought to you by the Bio Supply ... supply chain management professionals for the past 7 ... of the Biotech industry – Manufacturers, Service Providers, ...
(Date:7/24/2014)... , July 24, 2014  Now available is ... home. Rehealth Regenerative Therapies , located in ... other physically active people a new health option: ... Regardless of age, countless patients suffer from joint and ... such as muscle tears, torn rotator cuff, tennis elbow, ...
Breaking Biology Technology:Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4ORNL study reveals new characteristics of complex oxide surfaces 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3
... (NYSE: SGP ) today announced that the ... review status to the company,s,New Drug Application (NDA) ... reverse the effects of certain,muscle relaxants, marketed in ... bromide. Muscle relaxants are used as part of,general ...
... The following statement was issued,today by the law firm of ... given that a class action lawsuit was filed in the,United ... on,behalf of all purchasers of the securities of Sanofi-Aventis (NYSE: ... through June 13, 2007,inclusive (the "Class Period")., If you ...
... Dec. 31 Pharmasset, Inc.,(Nasdaq: VRUS ), ... and commercializing novel drugs to treat viral,infections, reported ... 30, 2007. Pharmasset reported a net loss attributable ... share, as compared to a net loss,attributable to ...
Cached Biology Technology:Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA 2Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA 3Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA 4Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 2Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 3Pharmasset Reports Fiscal Year End 2007 Financial Results 2Pharmasset Reports Fiscal Year End 2007 Financial Results 3Pharmasset Reports Fiscal Year End 2007 Financial Results 4Pharmasset Reports Fiscal Year End 2007 Financial Results 5Pharmasset Reports Fiscal Year End 2007 Financial Results 6Pharmasset Reports Fiscal Year End 2007 Financial Results 7Pharmasset Reports Fiscal Year End 2007 Financial Results 8Pharmasset Reports Fiscal Year End 2007 Financial Results 9
(Date:7/24/2014)... Scientists at The New York Stem Cell Foundation ... creating a viable cell replacement therapy for multiple ... For the first time, NYSCF scientists generated induced ... of patients with primary progressive multiple sclerosis and ... these stem cells into becoming oligodendrocytes, the myelin-forming ...
(Date:7/24/2014)... examples of how wildlife loss leads to conflict among ... Wildlife Conservation Society (WCS) Health & Ecosystems: Analysis ... for an interdisciplinary approach to tackle global biodiversity decline. ... 15% of the world,s people and provides protein for ... should come as no surprise that today,s unprecedented loss ...
(Date:7/24/2014)... - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) ... long-term, randomized, active control Phase 3 study of Zerenex ... binder, for the treatment of hyperphosphatemia in patients with ... (PhosphatE binding and iRon delivery with FErric CiTrate in ... of the American Society of Nephrology ( JASN ...
Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2New study draws links between wildlife loss and social conflicts 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
... identified several proteins in mice that might act as ... first step to finding a more reliable way to ... and teenagers use illegally to boost muscle and reduce ... in San Francisco today, scientists John Kopchick and Juan ...
... For those patients who receive the nearly 40 ... deficiency, a new oral option may soon exist. ... B12 deficiency can lead to a wide spectrum of ... Vitamin B12 deficiency is a significant health issue. Nearly ...
... ADHD-associated version of the human gene DRD4 is linked ... malnourishment in their settled cousins, according to new research ... University of Wisconsin-Milwaukee (UWM). A study by UWM ... Boston University and UNLV shows that a particular version ...
Cached Biology News:Scientists find potential protein biomarkers for growth hormone 2New technology may prevent vitamin B12 deficient seniors and vegetarians from needing injections 2Did the gene for ADHD help our nomadic ancestors? 2
... designed for two-dimensional electrophoresis (2D) and ... in this marker have been selected ... a 2D gel. The pI range ... Mol wt: 17,000-89,000 Physical Form: ...
... to test the crossreactivity of an antibody ... commonly used as blocking reagents or antigen ... different protein preparations on a nitrocellulose membrane. ... specificity, QC of purified antibodies, selection of ...
... is based on PI's experience in high-resolution ... a decade. PI Hexapods were originally used ... adjustments over wide ranges in small step ... freedom with 3 m minimum incremental motion ...
... can provide custom microplate coating using advanced automated high throughput ... plate formats. We can also accommodate virtually any lot size ... L):, , 8 and ... microplate, 384 well microplate, ...
Biology Products: